Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out

Next Previous
Trial Profile

A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms TOMORROW
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 30 Aug 2023 Results of pooled analysis from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02999178, NCT02597933, assessing decline in forced vital capacity (FVC) as a surrogate for mortality, published in the Respirology
  • 27 Dec 2021 Results published in the Advances in Therapy
  • 19 May 2021 Results of pooled analysis (n=2553) assessing decline in forced vital capacity (FVC) as a surrogate for mortality from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02597933 and NCT02999178 trials, presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top